recently approved drugs: olaparib for germline brca-mutated metastatic breast cancer
Published 5 months ago • 6 plays • Length 5:18Download video MP4
Download video MP3
Similar videos
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
3:02
mediola: olaparib and durvalumab for germline brca-mutated metastatic breast cancer
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
0:31
revolutionary cancer breakthrough - olaparib - life saving drug for brca tnbc
-
1:00:51
highlights from asco 2024
-
59:35
report back from asco 2024: latest updates on metastatic breast cancer (mbc)
-
49:27
grand rounds wash u st louis. issues with cancer trial design
-
2:23
fda approves new drug for metastatic breast cancer
-
7:36
asco 2022: metastatic breast cancer drug therapy recap
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
4:24
the latest treatment options for brca-mutated breast cancer
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
4:41
post neoadjuvant management in brca mutant breast cancer patients
-
8:39
#olaparib | uses, dosage, side effects & mechanism | lynparza
-
5:43
using olaparib in gbrca1/2 breast cancer
-
6:40
cancer topics - contrasting cases: systemic therapy for metastatic triple-negative breast cancer
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
2:57
olaparib and durvalumab in metastatic brca wild type triple-negative breast cancer
-
13:20
parp inhibitors for early, brca-mutant breast cancer - medpage today
-
2:46
systemic treatment of patients with metastatic breast cancer: asco resource-stratified guideline